文献速递神经核医学肿瘤 PET/CT核素与放射性配体治疗

胶质瘤PET成像前沿:神经肿瘤学家的当前应用与诊疗一体化突破路径

Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-31

本综述总结了胶质瘤PET成像的最新进展,重点讨论临床可用的氨基酸PET示踪剂,并概述新兴诊疗一体化策略(包括脑膜瘤的PRRT和高级别胶质瘤的177Lu-PSMA-617方法)。当前指南推荐氨基酸PET用于肿瘤与非肿瘤病变鉴别、胶质瘤范围勾画、分子信息无创预测、分级与预后评估、复发与治疗相关变化鉴别及治疗反应评价。

要点

  • 氨基酸PET被指南推荐用于胶质瘤鉴别诊断、范围勾画、分子预测、分级预后、复发鉴别和疗效评价。
  • PET作为MRI的补充成像模式,提供代谢与分子信息以辅助个体化治疗决策。
  • 新兴诊疗一体化策略包括脑膜瘤的PRRT和高级别胶质瘤的177Lu-PSMA-617方法。

核心结论

  • PET是MRI的补充成像模式,可提供代谢与分子信息,对神经肿瘤临床实践和患者结局具有潜在影响。

研究设计与样本

  • 本综述总结了胶质瘤PET成像的最新进展,重点为临床可用的氨基酸PET示踪剂。

主要发现

  • 放射性药物设计的持续创新通过提高示踪剂特异性和肿瘤检测灵敏度进一步改善了PET诊断性能。

关键数值与推荐

  • 当前指南推荐氨基酸PET用于肿瘤与非肿瘤病变鉴别、胶质瘤范围勾画、分子信息无创预测、分级与预后估计、复发与治疗相关变化鉴别及治疗反应评价。
  • 新兴诊疗一体化策略包括脑膜瘤的肽受体放射性核素治疗(PRRT)和高级别胶质瘤的177Lu-PSMA-617方法。

临床怎么用

  • 临床可将氨基酸PET作为MRI的补充,用于胶质瘤诊断、范围勾画、分子预测、分级预后、复发鉴别和疗效评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Positron emission tomography (PET) has become an increasingly important adjunct to brain MRI in the field of neuro-oncology. PET imaging utilizes radiolabeled tracers, providing in vivo assessment of the metabolic and molecular characteristics of gliomas, thereby providing functional data beyond standard anatomic images. This additional layer of crucial biological insight aids in personalized patient management and treatment decision. In recent years, numerous studies have been carried out for the development and clinical validation of several PET radiotracers in glioma imaging, leading to a substantial improvement in glioma diagnosis, staging, treatment strategy planning as well as in monitoring tumor progression and response to therapy. Ongoing innovations in radiopharmaceutical design have further improved the diagnostic performance of PET by increasing both tracer specificity and tumor detection sensitivity. METHODS: In this review, we summarize recent developments in PET imaging for glioma, with particular emphasis on clinically available amino acid PET tracers. In addition, we provide an overview of emerging theranostic strategies, including peptide receptor radionuclide therapy (PRRT) for meningioma and 177Lu-PSMA-617-based approaches for high-grade glioma. RESULTS: The current guidelines recommend the use of amino acid PET for differentiation of neoplastic from non-neoplastic lesions, for delineation of glioma extent, for non-invasive prediction of molecular information, for grading and prognosis estimation, for differentiation of glioma relapse from treatment-related changes and for the evaluation of treatment response. CONCLUSIONS: Overall, this work aims to highlight the role of PET as a complementary imaging modality to MRI and to discuss its potential impact on patient outcomes in neuro-oncological practice.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Gatto L, Mei R, Stasolla M, et al. Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs. Eur J Nucl Med Mol Imaging. 2026. PMID: 41617888. doi:10.1007/s00259-026-07777-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。